The stock of Novo Nordisk ADR (NVO) has gone down by -5.53% for the week, with a -14.04% drop in the past month and a -28.54% drop in the past quarter. The volatility ratio for the week is 2.08%, and the volatility levels for the past 30 days are 2.51% for NVO. The simple moving average for the last 20 days is -8.76% for NVO stock, with a simple moving average of -32.64% for the last 200 days.
Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?
Novo Nordisk ADR (NYSE: NVO) has a price-to-earnings ratio that is above its average at 23.07x. The stock has a 36-month beta value of 0.56. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 1 as “sell.”
The public float for NVO is 3.36B, and at present, short sellers hold a 0.40% of that float. On March 24, 2025, the average trading volume of NVO was 8.45M shares.
NVO) stock’s latest price update
Novo Nordisk ADR (NYSE: NVO) has seen a decline in its stock price by -1.49 in relation to its previous close of 76.86. However, the company has experienced a -5.53% decline in its stock price over the last five trading sessions. accessnewswire.com reported 2025-03-24 that NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=138262&wire=1 or contact Joseph E. Levi, Esq.
NVO Trading at -9.27% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.89% of loss for the given period.
Volatility was left at 2.51%, however, over the last 30 days, the volatility rate increased by 2.08%, as shares sank -16.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.69% lower at present.
During the last 5 trading sessions, NVO fell by -5.65%, which changed the moving average for the period of 200-days by -45.95% in comparison to the 20-day moving average, which settled at $82.98. In addition, Novo Nordisk ADR saw -11.98% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.44 for the present operating margin
- 0.85 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.35. The total capital return value is set at 0.52. Equity return is now at value 82.03, with 26.33 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 1.18. The debt to equity ratio resting at 0.72. The interest coverage ratio of the stock is 28.85.
Currently, EBITDA for the company is 137.38 billion with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 8.28. The receivables turnover for the company is 3.32for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To sum up, Novo Nordisk ADR (NVO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
